Get all your news in one place.
100’s of premium titles.
One app.
Start reading
Vandana Singh

Exact Sciences Clocks 16% Jump In Q4 Non-COVID-19 Revenues

Exact Sciences Corp's (NASDAQ:EXASQ4 revenues increased 2% Y/Y to $473.8 million and beat the average Wall Street estimate of $449 million.

  • Excluding COVID-19 testing revenues, which dropped 52% to $47.1 million, Exact's Q4 revenue increased 16%. 
  • Screening revenues rose 11% to $277.7 million in Q4, while precision oncology revenues were up 27% at $149 million.
  • The firm attributed its screening revenue growth to more Cologuard rescreens, growing use of the test in the 45-49 age group, expansion of its primary care sales team, and increased in-person sales calls.
  • Exact reported a Q4 EPS loss of $(1.28), compared to $(2.67) a year ago. Analysts had expected a lower loss of $1.04 per share.
  • Exact ended the year with $315.5 million in cash and cash equivalents and $715 million in marketable securities.
  • Guidance: Exact anticipates FY22 revenue of $1.97 billion - $2.03 billion, compared to consensus of $1.99 billion.
  • The outlook assumes screening revenues between $1.34 billion - 1.37 billion, at least $40 million of which should come from testing by its recent acquisition of PreventionGenetics.
  • The Company expects precision oncology revenue of $595 million to $610 million and COVID-19 testing revenue between $40 million and $50 million during the year.
  • Price Action: EXAS shares traded 8.06% lower at $67.53 on the last check Wednesday.
Sign up to read this article
Read news from 100’s of titles, curated specifically for you.
Already a member? Sign in here
Related Stories
Top stories on inkl right now
One subscription that gives you access to news from hundreds of sites
Already a member? Sign in here
Our Picks
Fourteen days free
Download the app
One app. One membership.
100+ trusted global sources.